Contineum Therapeutics, Inc. (NasdaqGS: CTNM)
Health Care · Pharmaceuticals · US
$17.05
+2.53% today · +64.1% 1Y
Contineum Therapeutics, Inc. (NasdaqGS: CTNM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $641.44M and employs 51 people.
Over the last twelve months the share price has gained 64.1%, trading between 8.60 and 17.35.
Tweenvest scores Contineum Therapeutics, Inc. across four factors: quality 74/100. Its strongest factor is quality.
CTNM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $641.44M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.72
- Dividend yield
- —
- Beta (5Y)
- 0.74
- 52-week high
- $17.35
- 52-week low
- $8.60
- Avg volume (3M)
- —
- Shares outstanding
- 37.62M
- Employees
- 51
- Next earnings
- —
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
- ISIN
- US21217B1008
- Founded
- 2009
- Listed since
- Apr 4, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,234.00 | +0.03% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.18 | +0.01% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.90 | -0.35% |
| Roche Holding AGSWX: ROP | $371.62B | CHF370.90 | -0.78% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.18 | -1.27% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.50 | -0.25% |
Figures last refreshed Aug 18, 2026.